Matt Kalnik wants to make smoking less addictive.
His clinical-stage company, Gaithersburg-based Antidote Therapeutics Inc., is developing a drug that would diminish the effects of nicotine in the body — to both treat diseases worsened by nicotine and help smokers quit. The businesses is looking to raise between $5 million and $10 million to run over the next two years and get its lead candidate to clinical trials.